Weeks 4, 8, and 12 were exploratory prespecified endpoints in the trial. By 4 weeks, Xultophy® 100/3.6 significantly reduced FPG vs insulin glargine U-100.
Post-hoc analysis: change in FPG over time1,2
Change in mean FPG for insulin degludec/liraglutide was –50.9 mg/dL; for insulin glargine, –49.9 mg/dL.
ETD=estimated treatment difference.
A 26-week, randomized, parallel, open-label, treat-to-target trial in adult patients with type 2 diabetes inadequately controlled (A1C 7%-10%) on insulin glargine U-100 (20-50 units) + metformin, comparing the efficacy and safety of Xultophy® 100/3.6 (n=278) with continued up-titration of insulin glargine U-100 (n=279), both + metformin. The primary endpoint was change in A1C after 26 weeks of treatment. Secondary endpoints included change in laboratory-measured FPG, dose, change in body weight, percent of patients achieving A1C <7%, and episodes of hypoglycemia.1,2